Guess which ASX healthcare share is rocketing 67% on a US hospital deal

Here are the details of the company's new hospital contract.

Key points
  • This healthcare share is soaring 67% today
  • The company has signed its maiden US hospital Software as a Service contract 
  • The healthcare sector is up 1.03% in late trading

This ASX healthcare share is rocketing ahead on the market today.

The 4DMedical Ltd (ASX: 4DX) share price is up 66.7% on yesterday's closing price, currently trading at an intraday high of 52.5 cents. It closed trading yesterday at 31.5 cents a share.

For perspective, the S&P/ASX 200 Healthcare Index (ASX: XHJ) is up 1.03% in late afternoon trade.

Let's take a look at why this ASX healthcare share is booming today.

A person with a round-mouthed expression clutches a device screen and looks shocked and surprised.

Image source: Getty Images

New five year contract

Investors appear to be buying up 4DMedical shares on the back of news it has signed its "first US hospital Software as a Service (SaaS) contract".

The company has signed a five-year contract with the University of Miami to deliver X-ray velocimetry lung ventilation analysis software ventilation reports.

Under the contract, 4DMedical will provide XV technology to the university to process patient data.

The deal represents a "significant milestone" for the company's commercialisation strategy in the United States.

Commenting on the news, 4DMedical and founder Andreas Fouras said:

Today's announcement of our first US SaaS contract reflects the attainment of a key milestone in the company's commercialisation journey.

Furthermore, the fact this milestone was completed with our clinical trial partners at the University of Miami, who have developed such an extensive understanding of XV Technology, is especially satisfying.

Share price snapshot

Even with today's boost, the 4DMedical share price has fallen 37% in the last year.

This ASX healthcare share has a market capitalisation of $141 million based on the current share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »